Author Search Results :: UTM Library Massive Scholar Tracking

1

Mutational analysis in serial marrow samples during azacitidine treatment in patients with post-transplant relapse of acute myeloid leukemia or myelodysplastic syndromes by Janghee Woo, Nicholas P. Howard, Barry E. Storer, Min Fang, Cecilia C. Yeung, Bart L. Scott, H. Joachim Deeg

Published 2017-06-01

Get full text

Article

2

$Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study$

Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study by Roland B. Walter, Bruno C. Medeiros, Kelda M. Gardner, Kaysey F. Orlowski, Leonel Gallegos, Bart L. Scott, Paul C. Hendrie, Elihu H. Estey

Published 2014-01-01

Get full text

Article

3

Correlation of clinical response and response duration with miR-145 induction by lenalidomide in CD34+ cells from patients with del(5q) myelodysplastic syndrome by Christopher P. Venner, Joanna Wegrzyn Woltosz, Thomas J. Nevill, H. Joachim Deeg, Gisela Caceres, Uwe Platzbecker, Bart L. Scott, Lubomir Sokol, Sandy Sung, Alan F. List, Aly Karsan

Published 2013-03-01

Get full text

Article

4

Impact of clinical, cytogenetic, and molecular profiles on long-term survival after transplantation in patients with chronic myelomonocytic leukemia by Janghee Woo, Dae Ro Choi, Barry E. Storer, Cecilia Yeung, Anna B. Halpern, Rachel B. Salit, Mohamed L. Sorror, David W. Woolston, Tim Monahan, Bart L. Scott, H. Joachim Deeg

Published 2020-03-01

Get full text

Article

5

Total body irradiation dose escalation decreases risk of progression and graft rejection after hematopoietic cell transplantation for myelodysplastic syndromes or myeloproliferativ... by Federico Monaco, Bart L. Scott, Thomas R. Chauncey, Finn B. Petersen, Barry E. Storer, Frederic Baron, Mary E. Flowers, H. Joachim Deeg, David G. Maloney, Rainer Storb, Brenda M. Sandmaier

Published 2019-06-01

Get full text

Article

6

High Molecular and Cytogenetic Risk in Myelofibrosis Does Not Benefit From Higher Intensity Conditioning Before Hematopoietic Cell Transplantation: An International Collaborative A... by Nico Gagelmann, Rachel B. Salit, Thomas Schroeder, Anita Badbaran, Christina Rautenberg, Victoria Panagiota, Christine Wolschke, Felicitas Thol, Bruno Cassinat, Marie Robin, Michael Heuser, Hans Christian Reinhardt, Bart L. Scott, Nicolaus Kröger

Published 2022-10-01

Get full text

Article

7

Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia by Srdan Verstovsek, Ruben Mesa, Moshe Talpaz, Jean-Jacques Kiladjian, Claire N. Harrison, Stephen T. Oh, Alessandro M. Vannucchi, Raajit Rampal, Bart L. Scott, Sarah A. Buckley, Adam R. Craig, Karisse Roman-Torres, John O. Mascarenhas

Published 2021-09-01

Get full text

Article

8

<i>Erratum</i> to: Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia by Srdan Verstovsek, Ruben Mesa, Moshe Talpaz, Jean-Jacques Kiladjian, Claire N. Harrison, Stephen T. Oh, Alessandro M. Vannucchi, Raajit Rampal, Bart L. Scott, Sarah A. Buckley, Adam R. Craig, Karisse Roman-Torres, John O. Mascarenhas

Published 2024-04-01

Get full text

Article

9

Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm by Roland B. Walter, Megan Othus, Kaysey F. Orlowski, Emily N. McDaniel, Bart L. Scott, Pamela S. Becker, Mary-Elizabeth M. Percival, Paul C. Hendrie, Bruno C. Medeiros, Michael T. Chiarella, Arthur C. Louie, Elihu H. Estey

Published 2018-03-01

Get full text

Article

10

$Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms$